For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $469.36 in the prior trading day, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) closed at $470.27, up 0.19%. In other words, the price has increased by $0.19 from its previous closing price. On the day, 1.48 million shares were traded. ALNY stock price reached its highest trading level at $485.28 during the session, while it also had its lowest trading level at $467.5001.
Ratios:
Our goal is to gain a better understanding of ALNY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 10.93 whereas as Long-Term Debt/Eq ratio is at 10.36.
On August 04, 2025, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $490.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 02 ’25 when Poulton Jeffrey V. sold 3,821 shares for $452.05 per share. The transaction valued at 1,727,284 led to the insider holds 54,052 shares of the business.
Greenstreet Yvonne sold 8,924 shares of ALNY for $4,034,085 on Oct 02 ’25. The Chief Executive Officer now owns 65,409 shares after completing the transaction at $452.05 per share. On Oct 02 ’25, another insider, Tanguler Tolga, who serves as the EVP, Chief Commercial Officer of the company, sold 1,405 shares for $452.05 each. As a result, the insider received 635,126 and left with 27,438 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALNY now has a Market Capitalization of 61642526720 and an Enterprise Value of 61524676608. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.04 while its Price-to-Book (P/B) ratio in mrq is 245.80. Its current Enterprise Value per Revenue stands at 24.99 whereas that against EBITDA is -497.422.
Stock Price History:
The Beta on a monthly basis for ALNY is 0.30, which has changed by 0.5847347 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, ALNY has reached a high of $484.21, while it has fallen to a 52-week low of $205.87. The 50-Day Moving Average of the stock is 3.64%, while the 200-Day Moving Average is calculated to be 46.03%.
Shares Statistics:
The stock has traded on average 1.17M shares per day over the past 3-months and 1135760 shares per day over the last 10 days, according to various share statistics. A total of 130.98M shares are outstanding, with a floating share count of 125.50M. Insiders hold about 4.26% of the company’s shares, while institutions hold 98.03% stake in the company. Shares short for ALNY as of 1759190400 were 3507540 with a Short Ratio of 3.01, compared to 1756425600 on 3973434. Therefore, it implies a Short% of Shares Outstanding of 3507540 and a Short% of Float of 3.53.
Earnings Estimates
The dynamic stock of Alnylam Pharmaceuticals Inc (ALNY) is currently attracting attention from 11.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $2.2, with high estimates of $4.34 and low estimates of $0.69.
Analysts are recommending an EPS of between $5.59 and $2.93 for the fiscal current year, implying an average EPS of $4.07. EPS for the following year is $10.13, with 13.0 analysts recommending between $19.87 and $4.15.
Revenue Estimates
24 analysts predict $946.13M in revenue for. The current quarter. It ranges from a high estimate of $1.27B to a low estimate of $654M. As of. The current estimate, Alnylam Pharmaceuticals Inc’s year-ago sales were $500.92MFor the next quarter, 24 analysts are estimating revenue of $1.21B. There is a high estimate of $1.4B for the next quarter, whereas the lowest estimate is $909M.
A total of 26 analysts have provided revenue estimates for ALNY’s current fiscal year. The highest revenue estimate was $3.84B, while the lowest revenue estimate was $2.87B, resulting in an average revenue estimate of $3.52B. In the same quarter a year ago, actual revenue was $2.25BBased on 26 analysts’ estimates, the company’s revenue will be $4.96B in the next fiscal year. The high estimate is $7.61B and the low estimate is $2.81B.
